文献速递哮喘

2型低度富集重度哮喘队列的急性加重特征与危险因素

Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

本研究为48周多中心随机对照临床试验的预设次要分析,纳入301例2型低度富集重度哮喘患者,按呼出气一氧化氮≤20 ppb且血嗜酸性粒细胞≤150 cells/µl定义为T2LOW。结果显示60.8%(183例)报告至少1次急性加重,T2LOW与T2HIGH急性加重在肺功能下降和症状加重上无差异,且炎症表型在个体内呈动态变化。

要点

  • T2LOW急性加重在肺功能下降与症状加重上与T2HIGH相似
  • T2LOW哮喘表型不稳定,应在急性加重时进行表型评估
  • 无2型生物学证据的急性加重提示非2型哮喘机制亟待阐明

核心结论

  • T2LOW表型的哮喘急性加重在生理和症状上与T2HIGH急性加重相似。
  • T2LOW哮喘是不稳定表型,提示急性加重表型评估应在急性加重时进行。
  • 无2型生物学证据的临床显著急性加重凸显理解非2型哮喘机制的迫切需求。

研究设计与样本

  • 48周、多中心、随机对照临床试验的预设次要分析,比较生物标志物与症状调整激素治疗。
  • 纳入2型低度富集重度哮喘队列,共301例参与者。
  • 在研究入组时及每次急性加重时进行T2LOW或T2HIGH表型判定。

主要发现

  • 301例中60.8%(183例)报告至少1次自报急性加重,共390次。
  • 急性加重者更可能为女性、体质指数更高、需口服糖皮质激素的急性加重及因急性加重非计划初级保健就诊更多。
  • 入组时23.6%(71例)为T2LOW,76.4%(230例)为T2HIGH。
  • T2LOW组哮喘初级保健就诊更多,更可能有既往HDU/ICU入住史并接受维持口服糖皮质激素。
  • 急性加重时T2LOW与T2HIGH在FEV1下降(200[400] ml vs 200[300] ml;P=0.93)和ACQ5症状增加(1.4[0.8] vs 1.3[0.8];P=0.72)上无差异。

关键数值与推荐

  • T2LOW定义:呼出气一氧化氮≤20 ppb且血嗜酸性粒细胞计数≤150 cells/µl。
  • T2HIGH定义:呼出气一氧化氮>20 ppb或血嗜酸性粒细胞计数>150 cells/µl。
  • T2LOW急性加重从稳定期到加重期T2生物标志物无升高。
  • 个体内炎症表型呈动态变化,入组时炎症表型与急性加重表型无显著关联。

临床怎么用

  • 对重度哮喘患者应在急性加重时而非仅稳定期评估炎症表型。
  • T2LOW表型患者即使缺乏2型生物标志物升高,仍可出现与T2HIGH相似的显著急性加重。
  • 对无2型生物学证据的急性加重需关注非2型机制并加强随访管理。

局限性

  • 本文为预设次要分析,非主要终点分析。
  • 急性加重为自报结局。
  • T2LOW与T2HIGH分组基于入组及加重时的生物标志物阈值判定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although present in a minority of patients with severe asthma, very little is known about the mechanisms underlying T2-low asthma, making it a significant unmet need in asthma research. Objectives: The objective of this study was to explore the differences between study exacerbators and nonexacerbators, to describe physiological changes at exacerbation in those who are T2HIGH and T2LOW at the time of exacerbation, and to evaluate the stability of inflammatory phenotypes when stable and at exacerbation. Methods: Exacerbation assessment was a prespecified secondary analysis of data from a 48-week, multicenter, randomized controlled clinical study comparing the use of biomarkers and symptoms to adjust steroid treatment in a T2-low severe asthma-enriched cohort. Participants were phenotyped as T2LOW (fractional exhaled nitric oxide ⩽ 20 ppb and blood eosinophil count ⩽ 150 cells/µl) or T2HIGH (fractional exhaled nitric oxide > 20 or blood eosinophil count > 150) at study enrollment and at each exacerbation. Here, we report the findings of the exacerbation analyses, including comparison of exacerbators and nonexacerbators, the physiological changes at exacerbation in those who had evidence of T2 biology at exacerbation versus those that did not, and the stability of inflammatory phenotypes when stable and at exacerbation. Measurements and Main Results: Of the 301 participants, 60.8% (183) had one or more self-reported exacerbations (total of 390). Exacerbators were more likely to be female, have a higher body mass index, and have more exacerbations requiring oral corticosteroid and unscheduled primary care attendances for exacerbations. At enrollment, 23.6% (71) were T2LOW and 76.4% (230) T2HIGH. The T2LOW group had more asthma primary care attendances, were more likely to have a previous admission to HDU (high dependency unit)/ICU and to be receiving maintenance oral corticosteroids. At exacerbation, the T2LOW events were indistinguishable from T2HIGH exacerbations in terms of lung function (mean fall in T2LOW FEV1, 200 [400] ml vs. T2HIGH 200 [300] ml; P = 0.93) and symptom increase (ACQ5: T2LOW, 1.4 [0.8] vs. T2HIGH, 1.3 [0.8]; P = 0.72), with no increase in T2 biomarkers from stable to exacerbation state in the T2LOW exacerbations. The inflammatory phenotype within individual patients was dynamic; inflammatory phenotype at study entry did not have a significant association with exacerbation phenotype. Conclusions: Asthma exacerbations demonstrating a T2LOW phenotype were physiologically and symptomatically similar to T2HIGH exacerbations. T2LOW asthma was an unstable phenotype, suggesting that exacerbation phenotyping should occur at the time of exacerbation. The clinically significant exacerbations in participants without evidence of T2 biology at the time of exacerbation highlight the unmet and pressing need to further understand the mechanisms at play in non-T2 asthma. Clinical trial registered with www.clinicaltrials.gov (NCT02717689).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. McDowell PJ, Busby J, Hanratty CE, et al. Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. Am J Respir Crit Care Med. 2022. PMID: 35549845. doi:10.1164/rccm.202201-0129OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。